NCT05896007View on ClinicalTrials.gov

Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
PCNSL
Interventions
DRUG

Zanubrutinib

160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up

DRUG

Rituximab

375 mg/m\^2 ivgtt, D0 of each 28-day cycle

DRUG

Methotrexate

3.5 g/m\^2 ivgtt, D1 of each 28-day cycle

DRUG

Temozolomide

150 mg/m\^2 ivgtt, D1-D5 of each 28-day cycle

Trial Locations (1)

20025

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER